



Attorney Docket No.: 6028.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Tina Meinertz Andersen

Serial No.: 09/661,696

Group Art Unit: To be assigned

Filed: September 14, 2000

Examiner: To be assigned

Confirmation No: 8978

For: Composition Containing a Meiosis Activating Substance

PATENT
TECH CENTER 1600/2900

OCT 24 2001

RECEIVED

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, DC 20231

on October 16, 2001.

Carol McFarlane-Fishberg
(name of person mailing paper)

Carol McFarlane-Fishberg
(signature of person mailing paper)



23650

PATENT TRADEMARK OFFICE

RECEIVED

OCT 24 2001

TECH CENTER 1600/2900

PATENT



Attorney Docket No.: 6028.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Tina Meinertz Andersen

Application No.: 09/661,696

Group Art Unit: To be assigned

Filed: September 14, 2000

Examiner: To be assigned

Confirmation No: 8978

For: Composition Containing a Meiosis Activating Substance

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:


1. U.S. Patent 4,175,074;
2. U.S. Patent 4,751,219;
3. WO 01/19354 A3;
4. WO 96/00235;
5. WO 99/13914;
6. WO 99/61010;
7. WO 96/00235;
8. WO 98/28323;
9. DD 253 491 A1;

10. WO 94/01090;
11. WO 98/24883;
12. WO 90/03429;
13. WO 00/52142;
14. WO 96/27658;
15. WO 98/55498;
16. WO 97/00884;
17. Byskov et al., J. Mol Med, Vol. 76, pgs. 818-823 (1998);
18. Buch et al., Arch. Pharm. Pharm. Med. Chem., Vol. 329, pgs. 399-402 (1996);
19. Willebrand et al., Acta pharmacol. et toxicol., Vol. 56, pgs. 228-232 (1985);
20. Fukudome et al., Biochimica et Biophysica Acta, Vol. 922, pgs. 155-161 (1987);
21. Kurono et al., Chem. Pharm. Bull., Vol. 35, pgs. 3045-3048 (1987);
22. Beng et al., Clinica Chimica Acta, Vol. 52, pgs. 257-269 (1974);
23. Olson et al., Journal of Parenteral Science & Technology, Vol. 42, pgs. 82-85 (1988);
24. Tanaka et al., J. Pharmacobio-Dyn, Vol. 9, pgs. 1015-1022 (1986); and
25. Fiume et al., Pharm. Acta Helv., Vol. 60, pgs. 318-320 (1985).

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed before the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,



Peter J. Waibel, Reg. No. 43,228
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

Date: October 16, 2001